BioCentury | Nov 7, 2018
Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
BC Innovations | Sep 29, 2016
Targets & Mechanisms

Two-timing Ebola

With five different Ebola viruses lurking in Africa and no way of knowing which will cause the next epidemic, the goal is to find a single drug to block them all. Now, two bispecific antibodies...
Items per page:
1 - 2 of 2